TP53 and acute myeloid leukemia: While we tested many AML cells with complex karyotypes in vitro and in vivo, the clinical response to Ven-PegC might differ depending on the number of aberrant chromosomes, presence of monosomy karyotype, or presence of TP53 mutation.